Steven M Nguyen1, Julian Sison2, Marjorie Jones3, Jesse L Berry4, Jonathan W Kim4, A Linn Murphree4, Vanessa Salinas5, Arthur J Olch6, Eric L Chang6, Kenneth K Wong7. 1. University of Central Florida College of Medicine, Orlando, Florida. 2. Robert Wood Johnson Medical School, Piscataway, New Jersey. 3. Pepperdine University, Malibu, California. 4. Department of Ophthalmology, Keck School of Medicine of USC and Children's Hospital Los Angeles, Los Angeles, California. 5. Division of Hematology/Oncology, City of Hope, Duarte, California. 6. Department of Radiation Oncology, Keck School of Medicine of USC and Children's Hospital Los Angeles, Los Angeles, California. 7. Department of Radiation Oncology, Keck School of Medicine of USC and Children's Hospital Los Angeles, Los Angeles, California. Electronic address: kewong@chla.usc.edu.
Abstract
PURPOSE: We retrospectively assessed the incidence of cataracts in patients with retinoblastoma (Rb) treated with either lens-sparing radiation therapy (LSRT) or whole-eye radiation therapy (WERT). A secondary aim of this study was to model the dose-response risk of cataract. METHODS AND MATERIALS: We reviewed 65 patients with Rb treated with radiation therapy (RT) at Children's Hospital, Los Angeles from 1997 to 2015. Eyes that were enucleated before RT or lacked follow-up eye examinations were excluded. All patients underwent computed tomography simulation, and mean lens dose data were collected. Follow-up ophthalmologic examinations and intraocular lens implant history were reviewed for cataracts. The primary event-free survival (EFS) outcome was cataract development. Eyes without cataracts were censored on the last date of eye examination or post-RT enucleation, if applicable. Kaplan-Meier estimates were used to compare EFS outcomes, and dose response was projected with Cox regression and logistic regression models. RESULTS: Sixty-one patients (94 eyes) were analyzed with a median follow-up of 51.8 months. For eyes treated with WERT, cataracts developed in 71.7% versus 35.3% for LSRT. Median EFS for WERT and LSRT were 20.8 and 67.9 months, respectively. Compared with WERT, a significant EFS benefit was demonstrated for LSRT (P < .001). Mean lens dose had a significant effect on cataracts in both Cox regression and logistic regression models (P < .01). The mean lens dose of 7 Gy was projected to have a 5-year cataract incidence of 20% and 25% with the logistic and Cox regression models, respectively. CONCLUSIONS: We report the first clinical data demonstrating significantly improved EFS in patients with Rb treated with LSRT. Through lens dose-response modeling, we validate a mean lens dose threshold of 7 Gy to keep cataract risk below 25%. Although RT is used less often for Rb owing to advances in chemotherapy delivery options, these findings are relevant for refining lens dose constraints, particularly in children who have received radiation dose near the orbit.
PURPOSE: We retrospectively assessed the incidence of cataracts in patients with retinoblastoma (Rb) treated with either lens-sparing radiation therapy (LSRT) or whole-eye radiation therapy (WERT). A secondary aim of this study was to model the dose-response risk of cataract. METHODS AND MATERIALS: We reviewed 65 patients with Rb treated with radiation therapy (RT) at Children's Hospital, Los Angeles from 1997 to 2015. Eyes that were enucleated before RT or lacked follow-up eye examinations were excluded. All patients underwent computed tomography simulation, and mean lens dose data were collected. Follow-up ophthalmologic examinations and intraocular lens implant history were reviewed for cataracts. The primary event-free survival (EFS) outcome was cataract development. Eyes without cataracts were censored on the last date of eye examination or post-RT enucleation, if applicable. Kaplan-Meier estimates were used to compare EFS outcomes, and dose response was projected with Cox regression and logistic regression models. RESULTS: Sixty-one patients (94 eyes) were analyzed with a median follow-up of 51.8 months. For eyes treated with WERT, cataracts developed in 71.7% versus 35.3% for LSRT. Median EFS for WERT and LSRT were 20.8 and 67.9 months, respectively. Compared with WERT, a significant EFS benefit was demonstrated for LSRT (P < .001). Mean lens dose had a significant effect on cataracts in both Cox regression and logistic regression models (P < .01). The mean lens dose of 7 Gy was projected to have a 5-year cataract incidence of 20% and 25% with the logistic and Cox regression models, respectively. CONCLUSIONS: We report the first clinical data demonstrating significantly improved EFS in patients with Rb treated with LSRT. Through lens dose-response modeling, we validate a mean lens dose threshold of 7 Gy to keep cataract risk below 25%. Although RT is used less often for Rb owing to advances in chemotherapy delivery options, these findings are relevant for refining lens dose constraints, particularly in children who have received radiation dose near the orbit.
Authors: Gabriel Chodick; Ruth A Kleinerman; Marilyn Stovall; David H Abramson; Johanna M Seddon; Susan A Smith; Margaret A Tucker Journal: Arch Ophthalmol Date: 2009-11
Authors: J C Hernandez; L W Brady; J A Shields; C L Shields; P DePotter; U L Karlsson; A M Markoe; B E Amendola; A Singh Journal: Int J Radiat Oncol Biol Phys Date: 1996-04-01 Impact factor: 7.038
Authors: M J Krasin; Bruce T Crawford; Y Zhu; E S Evans; M R Sontag; L E Kun; T E Merchant Journal: Clin Oncol (R Coll Radiol) Date: 2004-05 Impact factor: 4.126
Authors: Christopher C Denton; William S Gange; Hisham Abdel-Azim; Sonata Jodele; Neena Kapoor; Matthew J Oberley; Kenneth Wong; Jonathan Kim; Abby Vercio; Parisah Moghaddampour; K V Chalam; David Sierpina; Rebecca A Gardner; Michael A Pulsipher; Michael C Jensen; Aaron Nagiel Journal: Blood Adv Date: 2020-05-26
Authors: Bianca A W Hoeben; Enrica Seravalli; Amber M L Wood; Mirjam Bosman; Witold P Matysiak; John H Maduro; Astrid L H M W van Lier; Matteo Maspero; Gijsbert H Bol; Geert O Janssens Journal: Clin Transl Radiat Oncol Date: 2021-08-29